MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 18, 2005; DOI: 10.1124/mol.105.011338


0026-895X/05/6706-1822-1828$20.00
Mol Pharmacol 67:1822-1828, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.011338v1
67/6/1822    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lawrence, J.
Right arrow Articles by Venkateswarlu, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lawrence, J.
Right arrow Articles by Venkateswarlu, K.
ACCELERATED COMMUNICATION

Centaurin-{alpha}1, an ADP-Ribosylation Factor 6 GTPase Activating Protein, Inhibits {beta}2-Adrenoceptor Internalization

Joanna Lawrence, Stuart J. Mundell, Hongruo Yun, Eamonn Kelly, and Kanamarlapudi Venkateswarlu

Department of Pharmacology, University of Bristol, School of Medical Sciences, University Walk, Bristol, United Kingdom

The small GTP-binding protein ADP ribosylation factor 6 (ARF6) has recently been implicated in the internalization of G protein-coupled receptors (GPCRs), although its precise molecular mechanism in this process remains unclear. We have recently identified centaurin {alpha}1 as a GTPase activating protein (GAP) for ARF6. In the current study, we characterized the effects of centaurin {alpha}1 on the agonist-induced internalization of the {beta}2-adrenoceptor transiently expressed in human embryonic kidney (HEK) 293 cells. Using an enzyme-linked immunosorbent assay as well as confocal imaging of cells, we found that expression of centaurin {alpha}1 strongly inhibited the isoproterenol-induced internalization of {beta}2-adrenoceptor. On the other hand, expression of functionally inactive versions of centaurin {alpha}1, including an R49C mutant, which has no catalytic activity, and a double pleckstrin homology (PH) mutant (DM; R148C/R273C), which has mutations in both the PH domains of centaurin {alpha}1, rendering it unable to translocate to the cell membrane, were unable to inhibit {beta}2-adrenoceptor internalization. In addition, a constitutively active version of ARF6, ARF6Q67L, reversed the ability of centaurin {alpha}1 to inhibit {beta}2-adrenoceptor internalization. Finally, expression of centaurin {alpha}1 also inhibited the agonist-induced internalization of {beta}2-adrenoceptor endogenously expressed in HEK 293 cells, whereas the R49C and DM mutant versions of centaurin {alpha}1 had no effect. Together, these data indicate that by acting as an ARF6 GAP, centaurin {alpha}1 is able to switch off ARF6 and so inhibit its ability to mediate {beta}2-adrenoceptor internalization. Thus, ARF6 GAPs, such as centaurin {alpha}1, are likely to play a crucial role in GPCR trafficking by modulating the activity of ARF6.


Received January 21, 2005; accepted March 18, 2005

Address correspondence to: Kanamarlapudi Venkateswarlu, Department of Pharmacology, School of Medical Sciences, University of Bristol, University Walk, Bristol, BS8 1TD, United Kingdom. E-mail: k.venkateswarlu{at}bristol.ac.uk




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
K. Venkateswarlu, K. G. Brandom, and H. Yun
PI-3-kinase-dependent membrane recruitment of centaurin-{alpha}2 is essential for its effect on ARF6-mediated actin cytoskeleton reorganisation
J. Cell Sci., March 1, 2007; 120(5): 792 - 801.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics